Issue Date: July 25, 2016
Galenica to acquire Relypsa
Galenica, a midsized Swiss drugmaker, has agreed to acquire the California biotech firm Relypsa for $1.5 billion in cash. Founded in 2007, Relypsa develops polymeric medicines for patients with conditions that can be treated in the gastrointestinal tract. FDA approved its first product, a treatment for elevated blood potassium levels, in October 2015. The drug, Veltassa, is based on a fluorinated polymer manufactured by the fine chemicals companies Saltigo and Patheon.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society